24. Mint
IBS support — menthol, peppermint oil capsule RCTs, and Cochrane-level evidence.
Mint in 1 minute
What does it provide? Menthol (35–55% of essential oil), menthone, menthyl acetate, rosmarinic acid — IBS-symptom-reducing, antispasmodic, antimicrobial, antiemetic, and locally cooling.
How much? In the kitchen fresh mint 5–30 g/day, dried ½–1 tsp; for clinical use (IBS) enteric-coated peppermint oil capsule (0.2 ml = 187 mg/capsule), 1 capsule 3×/day (EMA, Cochrane).
When to avoid? GERD/reflux flare (menthol relaxes the lower esophageal sphincter), active gallstones, concentrated menthol on infants, high-dose essential oil in pregnancy.
Mint (Mentha spp.) has been a medicinal herb for over 2000 years — in Greek mythology, the underworld god Hades loved the nymph Minthe, who was trampled by his jealous wife Persephone, and Hades turned her into the mint plant for its life-evoking aroma. The classical Greek name "minthos" comes from there. Pliny and Dioscorides recommended it for digestion, headache, and topical cooling. Biblical writings (Luke 11:42) also mention the tithe of mint.
Peppermint (Mentha × piperita) is a natural hybrid of Mentha aquatica and Mentha spicata — first documented in 1696 by English botanist John Ray. The 1800s brought commercial cultivation in Europe and North America, and 20th-century pharmacy recognized peppermint oil as an official pharmacopoeial extract.
Clinical interest exploded with the 2007 Cappello meta-analysis: based on 8 RCTs, enteric-coated peppermint oil capsule significantly reduces IBS symptoms, with effectiveness similar to tricyclic antidepressants. The 2018 Khanna meta confirmed and expanded this — peppermint oil capsule is one of the best-researched "functional" digestive-supportive herbs. According to the 2016 Alammar meta, IBS symptoms decrease on average 39%. (BMJ 2007, BMC Complement Altern Med 2018)*
Scientific Background
Peppermint (Mentha × piperita) essential oil is 35–55% menthol-dominant, complemented by menthone (15–25%), menthyl acetate, 1,8-cineole, and menthofuran. Spearmint (Mentha spicata) is carvone-dominant (50–70%) and contains almost no menthol — so the two mints have clinically distinct profiles.
Menthol's multiple parallel mechanisms: TRPM8 receptor agonism (the cooling-sensation receptor), calcium channel inhibition (smooth muscle relaxation), 5-HT3 and 5-HT4 receptor modulation (antiemetic), and local anesthesia.
The most robust clinical evidence is in IBS support. Enteric-coated peppermint oil capsule (the capsule dissolves in the small intestine to avoid upper GI tract irritation) at 187 mg menthol three times daily shows NNT = 3 in meta-analysis (i.e., significant improvement in 1 of 3 patients).[2395][2396][2397] A 2016 meta-analysis documented an average 39% reduction in IBS symptoms, comparable in efficacy to tricyclic antidepressants. EMA/HMPC recognizes it under "well-established use" for IBS symptom reduction.[2398]
Functional dyspepsia: peppermint oil + caraway oil combination (an Iberogast component) showed symptom reduction in randomized trials.[2399]
Antimicrobial spectrum (in vitro): moderate — against Streptococcus mutans, Candida albicans, H. pylori. Explains the classic "mint candy for fresh breath" effect.
Anti-chemotherapy-induced nausea: small pilots and Cochrane-level reviews show peppermint inhalation is a moderate antiemetic adjunct.
GERD paradox: menthol relaxes the lower esophageal sphincter (LES) → worsens reflux. To be avoided in reflux patients. In infants, concentrated menthol applied topically carries a laryngospasm risk.[2400]
At the microbiome level, small pilots have shown menthol-selective antimicrobial effects and commensal support.
- + Hot drink (tea, classic Moroccan mint tea): classic digestive support.
- + Yogurt, raita (Indian/Middle Eastern): classic Mediterranean matrix.
- + Chocolate (after-eight, classic): modern dessert.
- + Lamb, meat (Greek/Turkish): flavor harmony.
- + Lemon, lime, ginger (mojito): classic Cuban.
- + Peppermint oil capsule + Iberogast/caraway: IBS synergy.
- In GERD/reflux flare: menthol relaxes the LES, worsens reflux.
- Active gallstones: choleretic effect potentiates the colic risk.
- Concentrated menthol topically on infants: respiratory laryngospasm risk (FDA warning).
- CYP3A4 substrates + high-dose peppermint oil: theoretical absorption interference.
- Long boiling: essential oil evaporates.
- Absorption-weakening drugs + oil capsule: separate in time.
- GERD, Barrett's esophagus, reflux flare: menthol worsens.
- Active gallstones, cholangitis: choleretic.
- Concentrated menthol topically or internally on infants and small children: to be avoided.
- Pregnancy (high-dose essential oil): caution.
- Hiatal hernia: menthol may worsen.
- Lamiaceae allergy: cross-reaction.
- Severe liver disease: high-dose essential oil to be avoided.
- Asthma flare: rare but reported bronchospasm trigger.
Daily serving
Fresh mint 5–30 g (1 tbsp finely chopped); clinical use peppermint oil capsule 0.2 ml = 187 mg, 1 capsule 3×/day before meals.
Preparation pattern
- Fresh leaf: chop finely before serving — high heat ruins it.
- Tea: fresh 5–10 leaves + 200 ml hot water, 5–10 min standing.
- Pesto-like mint sauce: mint + olive oil + almonds + parmesan.
- Clinical capsule: enteric-coated peppermint oil, 30 min before meal.
Classic patterns
Moroccan mint tea: green tea + fresh mint + sugar — classic.
Greek tzatziki: yogurt + cucumber + mint + garlic + olive oil.
Cuban mojito: rum + fresh mint + lime + sugar + soda.
IBS protocol: peppermint oil capsule 1 capsule 3×/day before meals, 4 weeks.
Storage and what not to do
Storage: fresh mint "flower-style" in water, refrigerated 1 week; dried 1 year airtight in a dark place.
What not to do: don't combine peppermint oil capsule in a GERD flare; don't apply concentrated menthol to an infant's chest; don't cook fresh mint.
References
[2395] Cappello G et al. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial2007;39(6):530–536. Dig Liver Dis. Link
INTRODUCTION: The use of peppermint oil in treating the irritable bowel syndrome has been studied with variable results probably due to the presence of patients affected by small intestinal bacterial overgrowth, lactose intolerance or celiac disease that may have symptoms similar to irritable bowel syndrome. AIM: The aim of the study was to test the effectiveness of enteric-coated peppermint oil in patients with irritable bowel syndrome in whom small intestinal bacterial overgrowth, lactose intolerance and celiac disease were excluded. METHODS: Fifty-seven patients with irritable bowel syndrome according to the Rome II criteria, with normal lactose and lactulose breath tests and negative antibody screening for celiac disease, were treated with peppermint oil (two enteric-coated capsules twice per day or placebo) for 4 weeks in a double blind study. The symptoms were assessed before therapy (T(0)), after the first 4 weeks of therapy (T(4)) and 4 weeks after the end of therapy (T(8)). The symptoms evaluated were: abdominal bloating, abdominal pain or discomfort, diarrhoea, constipation, feeling of incomplete evacuation, pain at defecation, passage of gas or mucus and urgency at defecation. For each symptom intensity and frequency from 0 to 4 were scored.
[2396] Khanna R et al. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis2014;48(6):505–512. J Clin Gastroenterol. Link
GOALS: The aim of this study was to assess the efficacy and safety of enteric-coated peppermint oil capsules compared with placebo for the treatment of active irritable bowel syndrome (IBS). BACKGROUND: IBS is a common disorder that is often encountered in clinical practice. Medical interventions are limited and the focus is on symptom control. STUDY: Randomized placebo-controlled trials with a minimum treatment duration of 2 weeks were considered for inclusion. Cross-over studies that provided outcome data before the first cross-over were included. A literature search upto February 2013 identified all applicable randomized-controlled trials.
[2397] Alammar N et al. The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis2019;19(1):21. BMC Complement Altern Med. Link
BACKGROUND: Peppermint oil (PO) has intrinsic properties that may benefit patients with irritable bowel syndrome (IBS) symptoms. The study objective was to determine the effect of peppermint oil in the treatment of the IBS. METHODS: We systematically searched MEDLINE (PubMed), Cochrane Central Register of Controlled Trials (Cochrane CENTRAL), ClinicalTrials.gov, EMBASE (Ovid), and Web of Science for randomized controlled trials (RCTs) of PO for IBS. We appraised the eligible studies by the Cochrane risk of bias tool. We performed random-effects meta-analysis on primary outcomes including global improvement in IBS symptoms and abdominal pain. A PRISMA-compliant study protocol is registered in PROSPERO Register [2016, CRD42016050917].
[2398] . EMA/HMPC 2020. European Union herbal monograph on Mentha × piperita L., folium. 2020. Link
EMA/HMPC European Union herbal monograph on peppermint (Mentha × piperita L.), folium.
[2399] Madisch A et al. Treatment of functional dyspepsia with a herbal preparation 2004. Digestion. 2004.
Clinical study on the treatment of functional dyspepsia with a herbal preparation.
[2400] FDA. Menthol — pediatric warning (laryngospasm).
FDA pediatric warning regarding the laryngospasm risk associated with menthol.
[2401] Ford AC et al. Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis 2019;114(1):21–39. Am J Gastroenterol. 2019. Link
An updated systematic review and meta-analysis of the effect of antidepressants and psychological therapies in irritable bowel syndrome (IBS). The authors searched MEDLINE, EMBASE, PsychINFO and the Cochrane register (up to July 2017); 53 randomized controlled trials reported in 51 articles were eligible (17 compared antidepressants with placebo, 35 compared psychological therapies with control/usual management, and one compared both). They concluded that antidepressants are efficacious in reducing IBS symptoms, and psychological therapies also appear effective, although the quality of evidence is limited and treatment effects may be overestimated.